Literature DB >> 26005705

New insights into 4E-BP1-regulated translation in cancer progression and metastasis.

Jun Wang1, Qing Ye1, Qing-Bai She1.   

Abstract

Remarkable progress has been made highlighting the importance of cap-dependent mRNA translation in cancer progression. 4E-BP1 is a translation initiation repressor by sequestering the mRNA cap-binding protein eIF4E and consequently inhibiting the translation of certain key oncogenic mRNAs encoding proteins for cell proliferation, survival, angiogenesis and malignancy. In most tumors, however, the repressive function of 4E-BP1 is compromised by reduction of its expression or phosphorylation mediated by oncogenic signaling pathways. We recently unveiled that 4E-BP1-regulated cap-dependent translation integrates oncogenic effects of the AKT and ERK signaling pathways on tumor growth and metastatic progression. Mechanistically, we demonstrate that AKT and ERK pathways selectively upregulate survivin expression at the level of translation by convergent activation of the mTORC1/4E-BP1/eIF4E signaling axis. In addition, loss of 4E-BP1 function induces epithelial-mesenchymal transition and increases metastatic capability of cancer cells by translational activation of Snail. Continuous translation of survivin and Snail is important for colorectal cancer progression to metastasis. Herein we discuss our findings concerning deregulation of translation in cancer progression and metastasis and highlight 4E-BP1 as a potential biomarker and therapeutic target.

Entities:  

Keywords:  4E-BP1; AKT; EMT; ERK; Snail; Survivin; mTOR; metastasis; translational regulation; tumorigenesis

Year:  2014        PMID: 26005705      PMCID: PMC4440693          DOI: 10.14800/ccm.331

Source DB:  PubMed          Journal:  Cancer Cell Microenviron


  64 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

Review 2.  The RTK/RAS/BRAF/PI3K pathways in melanoma: biology, small molecule inhibitors, and potential applications.

Authors:  Frank Haluska; Trevor Pemberton; Nageatte Ibrahim; Kevin Kalinsky
Journal:  Semin Oncol       Date:  2007-12       Impact factor: 4.929

Review 3.  Global signatures of protein and mRNA expression levels.

Authors:  Raquel de Sousa Abreu; Luiz O Penalva; Edward M Marcotte; Christine Vogel
Journal:  Mol Biosyst       Date:  2009-10-01

4.  mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

Authors:  Yanjie Zhang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

5.  Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model.

Authors:  Nicolas Floc'h; Carolyn Waugh Kinkade; Takashi Kobayashi; Alvaro Aytes; Celine Lefebvre; Antonina Mitrofanova; Robert D Cardiff; Andrea Califano; Michael M Shen; Cory Abate-Shen
Journal:  Cancer Res       Date:  2012-07-19       Impact factor: 12.701

6.  Reversing chemoresistance by small molecule inhibition of the translation initiation complex eIF4F.

Authors:  Regina Cencic; David R Hall; Francis Robert; Yuhong Du; Jaeki Min; Lian Li; Min Qui; Iestyn Lewis; Serdar Kurtkaya; Ray Dingledine; Haian Fu; Dima Kozakov; Sandor Vajda; Jerry Pelletier
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-29       Impact factor: 11.205

7.  Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer.

Authors:  Peng Hou; Dingxie Liu; Yuan Shan; Shuiying Hu; Kimberley Studeman; Stephen Condouris; Yangang Wang; Ariel Trink; Adel K El-Naggar; Giovanni Tallini; Vasily Vasko; Mingzhao Xing
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

8.  Repression of cap-dependent translation attenuates the transformed phenotype in non-small cell lung cancer both in vitro and in vivo.

Authors:  Blake A Jacobson; Michael D Alter; Marian G Kratzke; Sandra P Frizelle; Ying Zhang; Mark S Peterson; Svetlana Avdulov; Riikka P Mohorn; Bryan A Whitson; Peter B Bitterman; Vitaly A Polunovsky; Robert A Kratzke
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

9.  Eukaryotic initiation factor 4E binding protein family of proteins: sentinels at a translational control checkpoint in lung tumor defense.

Authors:  Yong Y Kim; Linda Von Weymarn; Ola Larsson; Danhua Fan; Jon M Underwood; Mark S Peterson; Stephen S Hecht; Vitaly A Polunovsky; Peter B Bitterman
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

10.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

View more
  9 in total

1.  Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.

Authors:  Zhongyuan Gao; Ting Yuan; Xiao Zhou; Ping Ni; Geng Sun; Ping Li; Zhixiang Cheng; Xuerong Wang
Journal:  Cancer Biol Ther       Date:  2018-02-06       Impact factor: 4.742

Review 2.  Macrophages and pancreatic ductal adenocarcinoma.

Authors:  Aida Habtezion; Mouad Edderkaoui; Stephen J Pandol
Journal:  Cancer Lett       Date:  2015-12-18       Impact factor: 8.679

3.  AKT inhibition overcomes rapamycin resistance by enhancing the repressive function of PRAS40 on mTORC1/4E-BP1 axis.

Authors:  Wenting Mi; Qing Ye; Side Liu; Qing-Bai She
Journal:  Oncotarget       Date:  2015-06-10

4.  eIF4E binding protein 1 expression is associated with clinical survival outcomes in colorectal cancer.

Authors:  Min-Wu Chao; Li-Ting Wang; Chin-Yu Lai; Xiao-Ming Yang; Ya-Wen Cheng; Kuo-Hsiung Lee; Shiow-Lin Pan; Che-Ming Teng
Journal:  Oncotarget       Date:  2015-09-15

5.  AEG-1 induces gastric cancer metastasis by upregulation of eIF4E expression.

Authors:  Shengjie Wu; Li Yang; Dandan Wu; Zhongyuan Gao; Ping Li; Wenbin Huang; Xuerong Wang
Journal:  J Cell Mol Med       Date:  2017-06-29       Impact factor: 5.310

6.  AEG-1 promotes the growth of gastric cancer through the upregulation of eIF4E expression.

Authors:  Shengjie Wu; Zuhao Zhang; Dandan Wu; Hongling Chen; Xixi Qian; Xuerong Wang; Wenbin Huang
Journal:  Onco Targets Ther       Date:  2019-07-22       Impact factor: 4.147

7.  Phosphorylated 4EBP1 is associated with tumor progression and poor prognosis in Xp11.2 translocation renal cell carcinoma.

Authors:  Yuanyuan Qu; Rui Zhao; Hongkai Wang; Kun Chang; Xiaoqun Yang; Xiaoyan Zhou; Bo Dai; Yao Zhu; Guohai Shi; Hailiang Zhang; Dingwei Ye
Journal:  Sci Rep       Date:  2016-03-30       Impact factor: 4.379

8.  ANGPTL4 Induces TMZ Resistance of Glioblastoma by Promoting Cancer Stemness Enrichment via the EGFR/AKT/4E-BP1 Cascade.

Authors:  Yu-Ting Tsai; An-Chih Wu; Wen-Bin Yang; Tzu-Jen Kao; Jian-Ying Chuang; Wen-Chang Chang; Tsung-I Hsu
Journal:  Int J Mol Sci       Date:  2019-11-11       Impact factor: 5.923

9.  Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.

Authors:  Jing Gao; Michelle Y Wang; Yuan Ren; Tint Lwin; Tao Li; Joy C Yan; Eduardo M Sotomayor; Derek R Duckett; Bijal D Shah; Kenneth H Shain; Xiaohong Zhao; Jianguo Tao
Journal:  Haematologica       Date:  2022-05-01       Impact factor: 11.047

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.